DOI: http://dx.doi.org/10.18203/2349-2902.isj20203486

Clinicopathological characterization and correlation of breast tumour with receptor status

Arvind Kanwar, Parikshit Malhotra, Vikram Singh, U. K. Chandel, Dhruv Sharma, Arun Chauhan

Abstract


Background: Malignancy of breast is the leading cause of cancer deaths in women. Molecular organisation of breast cancer is considered as better predictive factor for diagnosis and treatment. The present study was done with the aim to find out clinicopathological characterization and correlation of breast tumor with receptor status progesterone (PR), estrogen (ER) and human epidermal receptor protein-2/neu status (HER-2/neu).

Methods: This was a prospective study done on 50 patients with breast carcinoma. The expression patterns of PR, ER and HER-2/NEU were studied. Clinical features, pathologic features such as age of the patient, tumour size, grade, and lymph node status and their correlation with receptors were compared.

Results: Of the 50 patients, ER positivity was seen in 42% cases, PR positivity in 32% and HER-2/neu (3+) in 30% cases. Majority of grade I tumors were ER and PR positive and majority of grade III tumors were triple negative. Triple negative profile was seen in secretory carcinoma. ER, PR and HER2 status was not significantly associated with age of the patients and tumour size. The immunohistochemical types ER/PR +ve Her2neu +ve and ER/PR -ve Her2neu -ve are significantly related to grading of tumours.

Conclusions: From the results, it was concluded that ER, PR and HER-2 status correlates well with histopathological grading. These results highlight the fact that molecular subtypes correlate with diagnosis and aid in targeted therapy. 


Keywords


Breast tumour, Estrogen receptor, Progesterone receptor, HER-2 neu

Full Text:

PDF

References


Bennis S, Abbass F, Akasbi Y, Znati K, Joutei KA, Mesbani OE, et al. Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res Notes. 2012;5:436-43.

National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In, Consolidated Report of Population Based Cancer Registries 2001-2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR); 2006:8-30.

Bangal VB, Shinde KK, Gavhane SP, Singh RK. Breast Carcinoma in women - A Rising threat. IJBAR. 2013;4:73-6.

Mudduwa LKB. Quick score of hormone receptor status of breast carcinoma: correlation with the other clinicopathological prognostic parameters. IJPM. 2009;52:159-63.

Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M. Prevalence of Hormone Receptors and HER2/neu in Breast Cancer Cases in Jordan. Pathol Oncol Res. 2006;12:83-6.

Dodiya H, Patel A, Patel D, Kaushal A, Vijay DG. Study of Hormone Receptors and Epidermal Growth Factor Expression in Invasive Breast Cancers in a Cohort of Western India. Indian J Clin Biochem. 2013;28(4):403-9.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.

Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg. 1990;125:107-13.

Sharma M, Sharma JD, Sarma A, Ahmed S, Kataki AC, Saxena R. Triple negative breast cancer in people of north east India: Critical insights gained at a regional cancer centre. Asian Pac J Cancer Prev. 2014;15:4507-11.

Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathology. 2008;21:8-15.

Patil VK, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer Targets Therapy. 2011;3:9-19.

Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913-24.

Puvitha RD, Shifa S. Breast Carcinoma, Receptor Status and Her2 neu Expression Revisited. Int J Sci Stud. 2016;3(10):52-8.

Ejam SS, Farhood RG. Estrogen and progesterone receptors overexpression in breast carcinoma and their correlation with ages of patients, histopathological types and grades of tumors. Med J Babylon. 2013;10:726-34.

Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer. 2011;48:391-6.

Ayoade BA, Tade AO, Salami BA. Clinical features and pattern of presentation of breast diseases in surgical outpatient clinic of a suburban tertiary hospital in South-West Nigeria. Niger J Surg. 2012;18:13-6.

Giuliano AE, Barth MA. Incidence and predictors of axillary metastasis in T1 carcinoma breast. J Amm College Surgeons. 1996;183:185-9.

Verma K, Mohan CR, Sarin R. carcinoma of Breast: Lymph node clearance with different operative procedures. IJS. 1983:477-83.

Park K. Park’s Textbook of Preventive and Social Medicine. 20 th ed. Jabalpur: M/s Banarasidas Bhanot Publishers; 2009.

Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer. 2010;47:16-22.

Liu X, Zheng Y, Qiao C, Qv F, Wang J, Ding B, et al. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics. Diagn Pathol. 2015;10:50.

Patak TB, Bashyal R, Pun CB, Shrestha S, Bastola S, Neupane S. Estrogen and progesterone receptor expression in breast carcinoma. J Pathol Nepal. 2011;1:100-3.

Rajesh NG. Correlation of ER, PR and Her2neu immuno profile with the morphological prognostic factors in breast cancer South Indian data. Regional Cancer Centre Bulletin. 2010;2:27-9.

Bhagat VM, Jha BM, Patel PR. Correlation of hormonal receptor and Her-2/neu expression in breast cancer: a study at tertiary care hospital in south Gujrat. Natl J Med Res. 2012;2:295-8.

Jain SA, Aggrawal L, Ameta A, Nadkarni S, Goyal A, Ranjan, et al. Study of ER, PR and HER-2/NEU reactivity pattern in the patient of Breast Cancer in northern part of India. IOSR-JDMS. 2014;13:9-19.

Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: a study of 798 tumors. Breast. 2000;9:267-70.

Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India. Asian Pacific J Cancer Prev. 2012;12:625-9.

Konecny G, Pauletti G, Pegram M. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-53.

Ratnatunga N, Liyanapathirana LVC. Hormone receptor expression and HER2/neu amplification in breast carcinoma in a cohort of Sri Lanka. Ceylon Med J. 2007;52:133-6.

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2over-expressionwithclinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol. 2008;6(1):1.

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathological features and survival. Clin Med Res. 2009;7:4-13.